Cencora Announces Strategic $5 Billion OneOncology Acquisition
Cencora, Inc. (NYSE: COR) recently made a hit in the healthcare landscape by agreeing to acquire a majority stake in OneOncology from TPG and other shareholders, marking a significant move toward enhancing its market position.
Understanding the Deal Structure
The deal is valued at approximately $5.0 billion, which includes about $3.6 billion in cash along with the retirement of Cencora's existing corporate debt that stands at approximately $1.3 billion. This substantial investment illustrates Cencora's commitment to expanding its healthcare offerings.
Valuation Metrics of OneOncology
Upon completion of the acquisition, OneOncology will hold an enterprise value of around $7.4 billion, with an equity valuation of nearly $6 billion. Notably, the management and affiliated practices of OneOncology will retain a minority stake, suggesting an ongoing collaborative approach.
Investment Rationale for OneOncology
Cencora’s investment in OneOncology is grounded in its mission to empower community medical practices. This model aims to enhance patient access to care while keeping costs lower than traditional hospital settings. By facilitating independence for these practices, Cencora not only broadens its influence but also addresses critical healthcare delivery challenges.
Projected Closing and Funding Plans
This strategic transaction is anticipated to finalize by the end of Cencora’s fiscal second quarter in 2026. To finance this acquisition, Cencora plans to pursue new debt financing strategies, indicating a robust approach to capital management.
Impact on EPS and Financial Guidance
Looking ahead, Cencora expects that the acquisition will be neutral to its adjusted diluted earnings per share (EPS) during the first year, after accounting for financing costs. Such strategic planning reflects the company's thoughtful approach towards growth and maintaining financial health.
Fiscal Guidance in Light of the Acquisition
In the wake of this acquisition announcement, Cencora is reiterating its fiscal 2026 guidance. The company anticipates a sales growth between 5% and 7%, building upon the $321.3 billion in sales reported for 2025. Furthermore, the pause in share repurchases signals a shift in focus towards leveraging opportunities for growth.
Long-Term Financial Projections and Adjustments
In light of the expected long-term contributions from OneOncology, Cencora is increasing its guidance for both adjusted operating income and adjusted diluted EPS. This proactive adjustment positions Cencora to achieve a growth range of 7% to 10% in operating income, and between 10% to 14% increase in EPS over the next several years.
COR Stock Activity
Following the acquisition announcement, Cencora's shares exhibited a minor uptick of 0.05%, trading at $346.16 during premarket hours, reflecting investor confidence amidst these transformative changes.
Frequently Asked Questions
What is the value of the Cencora and OneOncology deal?
The acquisition deal is valued at approximately $5 billion.
When is the acquisition expected to be finalized?
The deal is set to close by the end of Cencora’s fiscal 2026 second quarter.
How will Cencora finance the acquisition?
Cencora plans to fund the acquisition through new debt financing efforts.
What growth is Cencora predicting for fiscal 2026?
The company expects sales growth of 5%-7% from its 2025 sales figures.
How might this acquisition impact Cencora’s EPS?
Initially, Cencora expects the acquisition to be neutral to its adjusted diluted EPS in the first twelve months post-acquisition.
